Treatment of osteoporosis
First Claim
1. A method for treating or preventing osteoporosis in humans comprising administering to a subject afflicted with or at risk to osteoporosis a bone cell activating compound and a bone resorption inhibiting polyphosphonate according to a regimen consisting of two or more cylces, whereby each cycle consists of:
- (a) a bone activating period of from about 1 day to about 5 days during which a bone activating amount of a bone cell activating compound is administered daily to said subject;
followed by (b) a bone resorption inhibition period of from about 10 days to about 20 days during which ethane-1-hydroxy-1,1-diphosphonic acid, or a pharmaceutically-acceptable salt or ester thereof, is administered daily to said subject in an amount of from about 0.25 mgP/kg/day to about 3.3 mgP/kg/day;
followed by (c) a rest period of from about 30 days to about 60 days during which the subject receives neither a bone cell activating compound nor a bone resorption inhibiting polyphosphonate.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient. The method shortens the natural cycle time of bone formation/resorption, resulting in a faster bone build-up.
-
Citations
16 Claims
-
1. A method for treating or preventing osteoporosis in humans comprising administering to a subject afflicted with or at risk to osteoporosis a bone cell activating compound and a bone resorption inhibiting polyphosphonate according to a regimen consisting of two or more cylces, whereby each cycle consists of:
- (a) a bone activating period of from about 1 day to about 5 days during which a bone activating amount of a bone cell activating compound is administered daily to said subject;
followed by (b) a bone resorption inhibition period of from about 10 days to about 20 days during which ethane-1-hydroxy-1,1-diphosphonic acid, or a pharmaceutically-acceptable salt or ester thereof, is administered daily to said subject in an amount of from about 0.25 mgP/kg/day to about 3.3 mgP/kg/day;
followed by (c) a rest period of from about 30 days to about 60 days during which the subject receives neither a bone cell activating compound nor a bone resorption inhibiting polyphosphonate. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)
- (a) a bone activating period of from about 1 day to about 5 days during which a bone activating amount of a bone cell activating compound is administered daily to said subject;
-
12. The method of calim 2 wherein the bone cell activating compound is prostaglandin PGE2 and the bone activating amount is from about 0.1 mg/kg/day to about 25 mg/kg/day.
-
16. A method for treating or preventing osteoporosis in humans comprising administering to a subject afflicted with or at risk to osteoporosis inorganic phosphate and ethane-1-hydroxy-1,1-diphosphonic acid according to a regimen consisting of two or more cycles, whereby each cycle consists of:
- (a) a bone activating period of about 3 days during which about 30 mg P/kg, in the form of inorganic phosphate, is administered daily to said subject;
followed by (b) a bone resorption inhibition period of about 14 days during which said diphosphonic acid, or a pharmaceutically acceptble salt thereof, is administered daily to said subject at a rate of about 1.24 mg P/kg/day followed by (c) a rest period of about 45 days during which the subject received calcium at a rate of from about 500 mg/day to about 1000 mg/day and vitamin D at a rate of about 400 units per day.
- (a) a bone activating period of about 3 days during which about 30 mg P/kg, in the form of inorganic phosphate, is administered daily to said subject;
Specification